A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection
Science · 04.10.2024 · 386 (6717) · 69-75
DOI: 10.1126/science.adn4955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 04.10.2024. Verfasst von Mohamad-Gabriel Alameh und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Bacterial Toxins, Bacterial Vaccines, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Clostridioides difficile infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)–lipid nanoparticle (LNP) vaccine targeting C. difficile toxins and virulence factors. This multivalent vaccine elicited robust and long-lived systemic and mucosal antigen-specific humoral and cellular immune responses across animal models, independent of changes to the intestinal microbiota. Vaccination protected mice from lethal CDI in both primary and recurrent infection models, and inclusion of non-toxin cellular and spore antigens improved decolonization of toxigenic C. difficile from the gastrointestinal tract. Our studies demonstrate mRNA-LNP vaccine technology as a promising platform for the development of novel C. difficile therapeutics with potential for limiting acute disease and promoting bacterial decolonization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Division of Infectious Disease, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Mohamad-Gabriel Alameh, Alexa Semon, Yi-Gen Pan, James Knox, Rochelle C Glover, Kyle Bittinger, Haitao Hu, Srinivasa Reddy Bonam, Jeffrey R Maslanka, Paul J Planet, Ahmed M Moustafa, Benjamin Davis, Anik Chevrier, Mitchell Beattie, Robert H Mach, Marc Lavertu, Mark A Sellmyer, Ying Tam, Michael C Abt, Drew Weissman, Joseph P Zackular
Förderung
- NIAID NIH HHS
Zitieren
APA
Alameh, M. G., Semon, A., Bayard, N. U., Pan, Y. G., Dwivedi, G., Knox, J., Glover, R. C., Rangel, P. C., Tanes, C., Bittinger, K., She, Q., Hu, H., Bonam, S. R., Maslanka, J. R., Planet, P. J., Moustafa, A. M., Davis, B., Chevrier, A., Beattie, M., …, & Zackular, J. P. (2024). A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science, 386(6717), 69-75. https://doi.org/10.1126/science.adn4955
Vancouver
Alameh MG, Semon A, Bayard NU, Pan YG, Dwivedi G, Knox J, et al. A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science. 2024;386(6717):69-75. doi:10.1126/science.adn4955
BibTeX
@article{Alameh2024,
author = {Alameh, Mohamad-Gabriel and Semon, Alexa and Bayard, Nile U and Pan, Yi-Gen and Dwivedi, Garima and Knox, James and Glover, Rochelle C and Rangel, Paula C and Tanes, Ceylan and Bittinger, Kyle and She, Qianxuan and Hu, Haitao and Bonam, Srinivasa Reddy and Maslanka, Jeffrey R and Planet, Paul J and Moustafa, Ahmed M and Davis, Benjamin and Chevrier, Anik and Beattie, Mitchell and Ni, Houping and Blizard, Gabrielle and Furth, Emma E and Mach, Robert H and Lavertu, Marc and Sellmyer, Mark A and Tam, Ying and Abt, Michael C and Weissman, Drew and Zackular, Joseph P},
title = {A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection},
journal = {Science},
year = {2024},
volume = {386},
number = {6717},
pages = {69--75},
doi = {10.1126/science.adn4955}
}
EUVIMED